• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $MGNX

    MacroGenics Inc.

    Subscribe to $MGNX
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

    IPO Year: 2013

    Exchange: NASDAQ

    Website: macrogenics.com

    Peers

    $IMMP
    $INCY
    $XNCR
    $ZLAB

    Recent Analyst Ratings for MacroGenics Inc.

    DatePrice TargetRatingAnalyst
    11/7/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/1/2024Buy → Neutral
    BTIG Research
    7/31/2024$18.00 → $5.00Buy → Neutral
    B. Riley Securities
    7/31/2024Buy → Neutral
    Guggenheim
    5/10/2024$24.00 → $8.00Outperform → Market Perform
    BMO Capital Markets
    5/10/2024$29.00 → $7.00Buy → Hold
    Stifel
    5/10/2024Buy → Hold
    TD Cowen
    4/26/2024$25.00Buy
    B. Riley Securities
    4/9/2024Hold → Buy
    TD Cowen
    3/4/2024$12.00 → $24.00Buy
    BTIG Research
    See more ratings

    MacroGenics Inc. SEC Filings

    See more
    • SEC Form DEFA14A filed by MacroGenics Inc.

      DEFA14A - MACROGENICS INC (0001125345) (Filer)

      4/11/25 4:01:29 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by MacroGenics Inc.

      DEF 14A - MACROGENICS INC (0001125345) (Filer)

      4/11/25 4:00:50 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MACROGENICS INC (0001125345) (Filer)

      3/20/25 4:05:47 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by MacroGenics Inc.

      10-K - MACROGENICS INC (0001125345) (Filer)

      3/20/25 4:05:04 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by MacroGenics Inc.

      8-K - MACROGENICS INC (0001125345) (Filer)

      2/26/25 5:11:09 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by MacroGenics Inc.

      SCHEDULE 13G/A - MACROGENICS INC (0001125345) (Subject)

      2/14/25 2:39:02 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by MacroGenics Inc.

      SCHEDULE 13G - MACROGENICS INC (0001125345) (Subject)

      2/11/25 5:37:12 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Inc. filed SEC Form 8-K: Leadership Update

      8-K - MACROGENICS INC (0001125345) (Filer)

      11/21/24 4:32:11 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MACROGENICS INC (0001125345) (Filer)

      11/5/24 4:03:32 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by MacroGenics Inc.

      10-Q - MACROGENICS INC (0001125345) (Filer)

      11/5/24 4:02:44 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    MacroGenics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by MacroGenics Inc.

      SC 13G - MACROGENICS INC (0001125345) (Subject)

      11/20/24 10:44:27 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by MacroGenics Inc.

      SC 13G/A - MACROGENICS INC (0001125345) (Subject)

      11/14/24 5:13:06 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by MacroGenics Inc.

      SC 13G - MACROGENICS INC (0001125345) (Subject)

      6/4/24 4:53:11 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by MacroGenics Inc.

      SC 13G - MACROGENICS INC (0001125345) (Subject)

      5/21/24 4:12:39 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by MacroGenics Inc. (Amendment)

      SC 13G/A - MACROGENICS INC (0001125345) (Subject)

      2/14/24 5:01:36 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by MacroGenics Inc. (Amendment)

      SC 13G/A - MACROGENICS INC (0001125345) (Subject)

      2/14/24 2:29:04 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by MacroGenics Inc.

      SC 13G - MACROGENICS INC (0001125345) (Subject)

      2/14/24 10:04:37 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by MacroGenics Inc. (Amendment)

      SC 13G/A - MACROGENICS INC (0001125345) (Subject)

      2/13/24 5:08:11 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by MacroGenics Inc. (Amendment)

      SC 13G/A - MACROGENICS INC (0001125345) (Subject)

      2/13/24 6:13:55 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by MacroGenics Inc.

      SC 13G - MACROGENICS INC (0001125345) (Subject)

      10/30/23 4:45:58 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    MacroGenics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • MacroGenics downgraded by JMP Securities

      JMP Securities downgraded MacroGenics from Mkt Outperform to Mkt Perform

      11/7/24 6:29:13 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics downgraded by BTIG Research

      BTIG Research downgraded MacroGenics from Buy to Neutral

      8/1/24 6:28:50 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded MacroGenics from Buy to Neutral and set a new price target of $5.00 from $18.00 previously

      7/31/24 6:30:32 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics downgraded by Guggenheim

      Guggenheim downgraded MacroGenics from Buy to Neutral

      7/31/24 6:30:00 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded MacroGenics from Outperform to Market Perform and set a new price target of $8.00 from $24.00 previously

      5/10/24 7:43:30 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics downgraded by Stifel with a new price target

      Stifel downgraded MacroGenics from Buy to Hold and set a new price target of $7.00 from $29.00 previously

      5/10/24 7:42:59 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics downgraded by TD Cowen

      TD Cowen downgraded MacroGenics from Buy to Hold

      5/10/24 7:40:40 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on MacroGenics with a new price target

      B. Riley Securities initiated coverage of MacroGenics with a rating of Buy and set a new price target of $25.00

      4/26/24 7:29:31 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics upgraded by TD Cowen

      TD Cowen upgraded MacroGenics from Hold to Buy

      4/9/24 8:21:29 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research reiterated coverage on MacroGenics with a new price target

      BTIG Research reiterated coverage of MacroGenics with a rating of Buy and set a new price target of $24.00 from $12.00 previously

      3/4/24 9:29:29 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    MacroGenics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MacroGenics Announces Date of First Quarter 2025 Financial Results

      ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025.  The Company will not be hosting a conference call to discuss its financial results or corporate progress for the quarter ended March 31, 2025. The Company may resume its practice of hosting quarterly results conference calls in the future. About MacroGenics, Inc.MacroGenics (the Company) is a biopharm

      5/6/25 4:30:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics to Participate in Upcoming Investor Conference

      ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will participate in the following investor conference this month: The Citizens Life Sciences Conference (New York). Members of MacroGenics' management team will participate in a fireside chat on Thursday, May 8, 2025, at 10:30am ET. Management will also participate in one-on-one meetings. A webcast of the above presentation may be accessed under "Events & Presentations" in the Invest

      5/1/25 4:30:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

      Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030Discontinuing further internal clinical development of vobra duo; exploring potential partneringCash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway extended into the second half of 2026Conference call scheduled for today at 4:30 p.m. ET  ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical com

      3/20/25 4:02:38 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

      ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday, March 20, 2025. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 20, 2025, at 4:30 pm ET Conference Call Information To participate via telephone, please register in advance via this link. Upon registration, all telephone part

      3/6/25 7:30:00 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics to Participate in Upcoming Investor Conferences

      ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March: TD Cowen 45th Annual Healthcare Conference (Boston). MacroGenics' President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, March 5, 2025, at 10:30am ET. MacroGenics' management will also participate in one-on-one meetings. Leerink Partners 2025 Global Healthcare Conference (Miami).

      2/27/25 7:30:00 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics to Participate in Upcoming Investor Conference

      ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month: 7th Annual Evercore HealthCONx (Coral Gables, FL). MacroGenics' President and Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, December 4, 2024, at 7:30am ET. MacroGenics' management will also participate in one-on-one meetings. A webcast of the above presentation may

      12/2/24 4:30:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics to Participate in Upcoming Investor Conferences

      ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month: Guggenheim Securities Healthcare Innovation Conference (Boston). MacroGenics' Chief Operating Officer, Eric Risser, will participate in a fireside chat on Tuesday, November 12, 2024, at 4:00pm ET. MacroGenics' management will also participate in one-on-one meetings. Stifel 2024 Healthcare Conference (New York). MacroGenics' Pre

      11/6/24 4:30:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results

      Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte related to advancement of ZYNYZ®ADAM9-directed ADC (MGC028) Investigational New Drug (IND) application submitted to FDA Conference call scheduled for today at 4:30 p.m. ET  ROCKVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 

      11/5/24 4:01:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Announces Leadership Transition

      Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company's Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the t

      10/30/24 7:30:00 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

      ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2024 after the market closes on Tuesday, November 5, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 5, 2024, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance via this link. Upon registration, all telephone participants will receive a

      10/29/24 4:30:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    MacroGenics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Biotech Target N V bought $669,585 worth of shares (150,000 units at $4.46), increasing direct ownership by 2% to 9,929,963 units (SEC Form 4)

      4 - MACROGENICS INC (0001125345) (Issuer)

      10/4/23 3:31:17 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    MacroGenics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr VP, Research & CSO Bonvini Ezio converted options into 16,665 shares, increasing direct ownership by 15% to 124,414 units (SEC Form 4)

      4 - MACROGENICS INC (0001125345) (Issuer)

      2/19/25 4:31:12 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, CFO and Secretary Karrels James converted options into 14,998 shares and covered exercise/tax liability with 5,790 shares (SEC Form 4)

      4 - MACROGENICS INC (0001125345) (Issuer)

      2/19/25 4:29:59 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Koenig Scott converted options into 42,329 shares, increasing direct ownership by 6% to 777,415 units (SEC Form 4)

      4 - MACROGENICS INC (0001125345) (Issuer)

      2/19/25 4:28:50 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Senior VP and General Counsel Peters Jeffrey Stuart converted options into 13,332 shares and covered exercise/tax liability with 5,147 shares, increasing direct ownership by 148% to 13,711 units (SEC Form 4)

      4 - MACROGENICS INC (0001125345) (Issuer)

      2/19/25 4:25:47 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Risser Eric Blasius converted options into 16,665 shares and covered exercise/tax liability with 6,433 shares, increasing direct ownership by 22% to 55,989 units (SEC Form 4)

      4 - MACROGENICS INC (0001125345) (Issuer)

      2/19/25 4:24:26 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Controller & Treasurer Smith Beth Ann converted options into 1,095 shares and sold $1,083 worth of shares (423 units at $2.56), increasing direct ownership by 8% to 9,532 units (SEC Form 4)

      4 - MACROGENICS INC (0001125345) (Issuer)

      2/19/25 4:23:17 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sr VP, Technical Ops Spitznagel Thomas converted options into 13,332 shares and covered exercise/tax liability with 5,520 shares, increasing direct ownership by 57% to 21,402 units (SEC Form 4)

      4 - MACROGENICS INC (0001125345) (Issuer)

      2/19/25 4:22:09 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Eck Stephen L. converted options into 16,665 shares and covered exercise/tax liability with 4,942 shares, increasing direct ownership by 66% to 29,377 units (SEC Form 4)

      4 - MACROGENICS INC (0001125345) (Issuer)

      2/19/25 4:20:46 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Eck Stephen L. converted options into 11,168 shares and covered exercise/tax liability with 3,312 shares, increasing direct ownership by 80% to 17,654 units (SEC Form 4)

      4 - MACROGENICS INC (0001125345) (Issuer)

      2/11/25 8:34:43 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sr VP, Research & CSO Bonvini Ezio converted options into 11,168 shares and covered exercise/tax liability with 4,311 shares, increasing direct ownership by 7% to 107,749 units (SEC Form 4)

      4 - MACROGENICS INC (0001125345) (Issuer)

      2/11/25 8:33:56 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    MacroGenics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • MacroGenics Announces Leadership Transition

      Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company's Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the t

      10/30/24 7:30:00 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

      ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A. Liu and Meenu Chhabra Karson to its Board of Directors, effective January 3, 2023. Dr. Liu will serve as a member of MacroGenics' Science and Technology Committee and Ms. Karson will serve as a member of the Company's Audit Committee. Following the appointment of Dr. Liu and Ms. Karson, MacroGenics' Board will comprise ten directors, nine of whom are independent. "We are delighted to have both Margaret and Meenu join Ma

      1/4/23 4:30:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Announces Appointment of William Heiden to Board of Directors

      ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of William Heiden to its Board of Directors, effective May 22, 2022. Mr. Heiden will serve as Chair of the board and a member of the Audit Committee. Following the appointment of Mr. Heiden, the Board will comprise eight directors, seven of whom are independent. Mr. Heiden is replacing Paulo F. Costa as Chair. Mr. Costa served in the Chair position until his term as director expired on May 19, 2022.  "We are delighted to have Bill join Macr

      5/23/22 4:01:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Names Federica O’Brien to its Board of Directors

      ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica “Freddi” O’Brien, President of CFO’Brien Consulting, LLC, to its Board of Directors.  Federica O’Brien is a veteran executive with 25 years of financial and operational leadership in biopharmaceutical, medical device, and technology companies and currently serves on the Board of Directors of TELA Bio, Inc. where she also chairs the Audit Committee. Ms. O’Brien will be joining MacroGenics’ Audit Committee. "We are de

      2/11/21 4:30:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    MacroGenics Inc. Financials

    Live finance-specific insights

    See more
    • MacroGenics Announces Date of First Quarter 2025 Financial Results

      ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025.  The Company will not be hosting a conference call to discuss its financial results or corporate progress for the quarter ended March 31, 2025. The Company may resume its practice of hosting quarterly results conference calls in the future. About MacroGenics, Inc.MacroGenics (the Company) is a biopharm

      5/6/25 4:30:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

      Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030Discontinuing further internal clinical development of vobra duo; exploring potential partneringCash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway extended into the second half of 2026Conference call scheduled for today at 4:30 p.m. ET  ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical com

      3/20/25 4:02:38 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

      ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday, March 20, 2025. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 20, 2025, at 4:30 pm ET Conference Call Information To participate via telephone, please register in advance via this link. Upon registration, all telephone part

      3/6/25 7:30:00 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results

      Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte related to advancement of ZYNYZ®ADAM9-directed ADC (MGC028) Investigational New Drug (IND) application submitted to FDA Conference call scheduled for today at 4:30 p.m. ET  ROCKVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 

      11/5/24 4:01:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

      ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2024 after the market closes on Tuesday, November 5, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 5, 2024, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance via this link. Upon registration, all telephone participants will receive a

      10/29/24 4:30:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024

      Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing an extension of treatment duration as compared to Phase 1 mCRPC dose expansion cohortCompany expects to have mature median rPFS no later than early 2025MacroGenics to host an investor call to review key data presented at ESMO and provide a general corporate update on Monday, September 16, 2024, at 8:00 a.m. ET ROCKVILLE, MD, Sept. 15, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing

      9/15/24 3:00:00 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024

      ROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced a poster presentation relating to Phase 2 data of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain from September 13-17, 2024. The following poster will be available on Sunday, September 15, 2024: TAMARACK: Randomized Phase 2 trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitam

      9/8/24 7:10:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results

      Upcoming poster presentation of protocol-defined TAMARACK Phase 2 mCRPC study data at ESMO in SeptemberReceived $100.0 million in milestones related to Incyte's advancement of ZYNYZ® (retifanlimab-dlwr) subsequent to quarter-endConfirming cash runway guidance into 2026 ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2024. "We are pleased to have the opportunity to present

      8/6/24 4:01:41 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Provides Vobramitamab Duocarmazine Update

      Abstract of clinical data accepted for poster presentation at ESMO Congress 2024 in SeptemberESMO poster to include protocol-defined TAMARACK Phase 2 mCRPC study data, including pre-defined landmark primary endpoint of 6-month rPFS rate and updated safetyTreatment recently discontinued for TAMARACK mCRPC study participants who remained eligible for further dosing following review of totality of data, including efficacy, and emerging adverse events associated with prolonged exposure and considering potential risk/benefit to participants; most had received at least 8 cycles of vobra duoGiven embargoed TAMARACK data presentation at ESMO, Company plans to host an investor update call following E

      7/30/24 4:10:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data

      Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2024. "We are very encouraged by the interim updated safety and preliminary efficacy data from the TAMARACK study of vobra duo in metastatic castration-

      5/9/24 4:01:13 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    MacroGenics Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for MARGENZA issued to MACROGENICS INC

      Submission status for MACROGENICS INC's drug MARGENZA (SUPPL-5) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 05/25/2023. Application Category: BLA, Application Number: 761150, Application Classification:

      5/29/23 4:45:45 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for MARGENZA

      Submission status for MACROGENICS INC's drug MARGENZA (ORIG-1) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 12/16/2020. Application Category: BLA, Application Number: 761150, Application Classification:

      12/20/20 4:31:01 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care